MarketInOut Stock Screener Log In | Sign Up

Oramed Pharmaceuticals Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
Oramed Pharmaceuticals Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization173.04 mln
Float33.96 mln
Earnings Date07/14/2027

EPS

4.13
Solid

P / E

1.00
Deeply undervalued

Piotroski F-Score

5 / 9
Neutral

Relative Strength

67 / 100
Outperforming

Debt / Equity

0.00
Debt-free

ROE

78.54
Exceptional

Business Description

Oramed Pharmaceuticals is a New York-based drug development company focused on making it possible for patients to take insulin and other protein-based medicines as a pill rather than an injection. Its leading product, an oral insulin capsule called ORMD-0801, is currently in late-stage clinical trials for people living with diabetes. The company also holds licensing rights to develop oral vaccines targeting COVID-19 and related coronaviruses.

Key Fundamentals

EPS4.13
P/E1.00
ROE78.54
ROIC-7.34
ROA69.86
EBITDA, mln220
EV / EBITDA0.68
EV / EBIT0.68
Revenue, mln2.00
EV / Revenue75.04

Quote Details

Last 4.11
Change -0.12 (-2.84%)
Open 4.22
Volume 91,505
Turnover 376,086
Average Volume 124,039

Financial Ratios

Leverage Ratio1.16
Current Ratio4.98
Price / Book0.61
Price / Tangible Book0.61
Debt / Equity0.00
Price / Sales99.35

Financial Strength

Piotroski F-Score 5 / 9
Price to Intrinsic Value1.72
Price to Graham Number0.35
Short Ratio7.52
Short % of Float4.16

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -0.48% 44 / 100   
1 Month -8.26% 32 / 100   
2 Months -1.2% 51 / 100   
6 Months 3.27% 69 / 100   
1 Year 85.97% 96 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog